Spectrum Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
Spectrum Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
On September 2, 2025, it was reported that Spectrum Pharmaceuticals, Inc., listed as SPPI on NASDAQ, is the subject of a class action lawsuit filed by the DJS Law Group. This legal action pertains to violations of the securities exchange regulations, specifically §§10(b) and 20(a) of the Securities Exchange Act of 1934 along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission (SEC).
Background of the Case
The lawsuit concerns allegations that from March 17, 2022, to September 22, 2022, the company made numerous misleading statements regarding its drug poziotinib, aimed at treating lung cancer. The complaint asserts that the findings related to Spectrum's Pinnacle Study were less favorable than the company led investors to believe. As a result, Spectrum’s public disclosures during this period did not accurately reflect the reality of their clinical findings, leading to investor losses.
Individuals who bought shares of SPPI within the specified timeframe are strongly urged to reach out to the DJS Law Group to explore the possibility of becoming lead plaintiffs. Despite this, the firm has made it clear that one's appointment as lead plaintiff is not a prerequisite for recovering losses associated with this case.
Important Dates Anounced
- - Class Period: March 17, 2022, to September 22, 2022
- - Deadline for Lead Plaintiff Application: September 24, 2025
How to Get Involved
For shareholders who are affected by the reported misinformation, the DJS Law Group has emphasized that registering with them will allow for enrollment in portfolio monitoring software. This software will keep participants informed about the developments and progress of the case without incurring any costs or obligations on their part.
Why Choose DJS Law Group?
The DJS Law Group specializes in maximizing investor returns. They focus on legal representation in securities class action litigations, corporate governance disputes, and conducting domestic and international M&A appraisals. This law firm serves influential clients, including some of the world's largest hedge funds, reinforcing a reputation for aggressive advocacy and strategic balancing of interests.
If you are among those who have lost funds as a result of the alleged misinformation from Spectrum Pharmaceuticals, contacting DJS Law Group could be the essential step toward recovering your losses.
This press release may serve as attorney advertising in accordance with applicable regulations and ethical standards in certain jurisdictions.
For further inquiry, interested parties can contact:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.